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ORIGINAL ARTICLE
Prospective Investigation of the Performance of 2
Gamma-Hydroxybutyric Acid Tests: DrugCheck GHB
Single Test and Viva-E GHB Immunoassay
Thomas A. Smits, PharmD,* Femke M. J. Gresnigt, MD,† Bianca D. van Groen, PharmD,‡
Eric J. F. Franssen, PharmD, PhD,* and Milly E. Attema-de Jonge, PharmD, PhD§
Background: Gamma-hydroxybutyric acid (GHB) is a recreational
drug with central nervous system depressing effects that is often abused.
A urine GHB point-of-care test can be of great diagnostic value. The
objective of this prospective study was to determine the performance of
the new DrugCheck GHB Single Test and the Viva-E GHB
immunoassay for urine samples in emergency department patients.
Methods: Patients presented to the emergency department of the
OLVG hospital in Amsterdam with a Glasgow Coma Scale score
,15 and potential drug of abuse intoxication were included in the
study. Between June 2016 and October 2017, 375 patients were
included. Using the DrugCheck GHB Single Test (Express Diagnos-
tics Int’l, Blue Earth, MN) and the Viva-E GHB immunoassay (Sie-
mens Healthineers, The Hague, the Netherlands), patients’ urine
samples were tested for GHB (cutoff for a positive result, 10 or 50
mcg/mL GHB). To ensure quality, the results obtained were com-
pared with those generated using a validated gas chromatography
method. The tests were considered reliable if specificity and sensi-
tivity were both .90%. Possible cross-reactivity with ethanol was
investigated by analyzing ethanol concentrations in patients’
samples.
Results: Seventy percentage of the included patients was men, and
the median age was 34 years old. The DrugCheck GHB Single
Test’s specificity and sensitivity were 90.0% and 72.9%, respec-
tively, and using 50 mcg/mL as a cutoff value, its specificity and
sensitivity improved to 96.7% and 75.0%, respectively. Serum and
urine ethanol levels in the false-positive group were significantly
higher compared with those in the true-negative group. The speci-
ficity and sensitivity of the Viva-E GHB immunoassay (cutoff value
of 50 mcg/mL and excluding samples with ethanol levels $2.0 g/L)
were 99.4% and 93.5%, respectively.
Conclusions: The DrugCheck GHB Single Test’s specificity was
sufficient, whereas its sensitivity was poor, making it unsuitable for
use at point-of-care. Contrarily, using 50 mcg/mL as the cutoff value
and excluding samples with ethanol levels $2.0 g/L, the Viva-E
GHB immunoassay showed acceptable results to detect clinically
relevant GHB intoxications.
Key Words: GHB, point-of-care, immunoassay, ethanol, emergency
department
(Ther Drug Monit 2020;42:139–145)
INTRODUCTION
Gamma-hydroxybutyric acid (GHB), also known as
a rape drug and frequently used in party settings because of its
euphoria and libido-increasing effects (chemsex), is a central
nervous system depressant drug. Because of its narrow
therapeutic range, a small GHB overdose may result in
dizziness, sleepiness, hypothermia, or even coma with
respiratory depression.1–5 In the Netherlands, GHB abuse,
which has not changed over the past couple of years, is a sig-
nificant problem. In 2013 in Amsterdam, 12% of those who
attended rave parties were current users of GHB, and in 2016,
1.3% of the Dutch population ($18 years) had used GHB at
least once.6 Moreover, a shift from GHB use to the use of its
precursors gamma-butyrolactone and 1,4-butanediol (1,4-
BD), which are rapidly transformed to GHB in vivo and
can, therefore, result in intoxication, have recently been
described in the literature.5 GHB intoxication is a common
cause of impaired consciousness or coma reported at the
emergency department (ED) of the OLVG hospital, and each
year, about 100 ED visits to this large teaching hospital are
GHB-related. Therefore, GHB use is always considered in the
differential diagnosis of every patient with a low Glasgow
Coma Scale (GCS) score.
To date, it remains difficult to quickly confirm GHB
intoxication by rapid GHB detection in urine. Previous
studies on GHB analysis focused on enzymatic assays, as
well as colorimetric, mass spectrometry, and gas chromato-
graphy methods available in laboratories.7–12 In some
hospitals, the time-consuming gas chromatography with
flame ionization detection (GC–FID) method for GHB quan-
tification, which requires highly trained laboratory workers
for operation, is available. Obtaining a test result with this
method takes about 90 minutes, including sample preparation.
However, because of GHB’s short half-life (20–40
minutes),7,8,13–15 a diagnostic test in ED settings is only help-
ful if results are quickly available to guide additional
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diagnostic tests and treatment. In the past couple of years,
assays for rapid urine GHB detection based on enzymatic
methods have become available. Unfortunately, their reliabil-
ity was inconclusive and showed different results.9,16,17
GHB’s small nonspecific structural formula makes enzymatic
tests prone to cross-reactivity with other similar compounds
such as ethanol.9 Drogies et al18 reported a novel enzymatic
method (Bühlmann Laboratories, Schönenbuch, Switzerland)
that was used to measure GHB in serum of 13 patients. The
performance of this method was investigated by Hasan et al.
Its specificity in serum was 88.9% (cutoff value, 10 mcg/mL),
and in urine, it was 98.4% (cutoff value, 15 mcg/mL), indi-
cating a limited possibility of cross-reactivity and leading to
a few false-positive results.9 Furthermore, small amounts of
GHB are endogenously present in humans; therefore, a reli-
able method should be able to distinguish between physiolog-
ical concentrations and those resulting from exogenous
administration.10,19–21 The GHB’s cutoff value in the urine
needed to confirm exogenous administration is critical for
such methods to be reliable. In the literature, urine clinical
sample cutoff values of 10 and 15 mcg/mL have been
described because endogenous concentrations in the urine
vary between 1 and 10 mcg/mL.10,20–23 In this study, the
aim was to prospectively investigate the performance of the
new DrugCheck GHB Single Test and the Viva-E GHB
immunoassay in urine sample analysis in ED patients. The
DrugCheck GHB Single Test can be used by ED staff at
point-of-care for generating results within 10 minutes,
whereas the Viva-E GHB immunoassay, generally used in
hospital laboratory settings, is an attractive alternative that
can be used to generate results within 15 minutes.
MATERIALS AND METHODS
Study Design and Setting
This prospective study was conducted at the ED of the
OLVG hospital, a teaching hospital with 2 locations in central
Amsterdam (the Netherlands). This ED receives a total of
79,000 patients annually, including many tourists. Intoxica-
tions with drugs of abuse are common in the ED of the OLVG
hospital, with approximately 1000 intoxications each year.
Ethical approval for this study was obtained from the
hospital’s institutional review board, and the Medical
Research Ethics Committees United (MEC-U) waived the
need for a formal ethics approval according to the Dutch
law on medical research in humans.
Subjects
All patients presented at the ED of the OLVG hospital
between June 2016 and October 2017, with a differential
diagnosis including drugs of abuse intoxication, were
included in the study if their GCS score was below 15. In
addition, patients with a GCS score of 15 were also included
if GHB intoxication was suspected. Given that patients were
presented to the ED at different times, each visit was counted
as a new case. Urine and blood samples (in a B-NaF/KOx
tube) were collected by a nurse in compliance with routine
care, stored in a refrigerator (2–88C) for 24 hours, and
subsequently transferred into a freezer (2208C) within 1–3
days (See “Methods of measurement” for GHB stability). All
measurements were performed using residual specimen that
was available after routine care use. Patients were included if
urine was obtained.
Methods of Measurement
GHB On-Site Test
Urine samples were used to examine the performance
of the on-site DrugCheck GHB Test (Express Diagnostics
Int’l, Blue Earth, MN). This was further named as the “GHB
on-site test”, which is based on the reaction between GHB
and nicotinamide adenine dinucleotide (NAD), producing
NADH+ (catalyzed by GHB dehydrogenase). If GHB was
present, a diaphorase couple tetrazolium dye reaction will
change the color of the dipstick to purple. The GHB on-site
test dipstick was dipped into the urine sample for 5 seconds
and examined after 2 minutes (or after 10 minutes, if it was
not purple after 2 minutes).11,24 If urine GHB concentration
was higher than 10 mcg/mL, the result was considered pos-
itive for GHB.20,21 Results were stratified into 2 categories:
negative/endogenous (colorless, 0–10 mcg/mL) and positive/
exogenous (light purple, 10–50 mcg/mL; dark purple, .50
mcg/mL) (Fig. 1). According to the manufacturer, vitamin C
(ascorbic acid) interferes with the GHB on-site test and was
therefore checked with an additional dipstick in case of a pos-
itive GHB test.24 When its concentration appeared to be high-
er than 10 mg/dL, the GHB on-site test result was considered
unreliable, and such samples were not included in the GHB
on-site test’s performance analysis. In this study, the GHB on-
site test was performed by pharmaceutical laboratory workers
at the hospital pharmacy. Results were not shared with the
doctors, ensuring their treatment plan was not changed based
on the results of a nonvalidated test.
The Viva-E GHB Immunoassay
Given that the GHB on-site test could produce unreli-
able results, we tested an alternative fast GHB quantification
method: the Viva-E GHB immunoassay (Siemens Healthi-
neers, the Hague, the Netherlands), in combination with
a GHB enzymatic assay kit (Bühlmann Laboratories,
FIGURE 1. Reference colors to quantify urine GHB and vitamin
C using the DrugCheck GHB Single Test.24
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Schönenbuch, Switzerland). This assay was also based on
GHB-induced NADH+ production, where a shift in absor-
bance was correlated with the GHB concentration.25 It is
a laboratory-based assay that produces sample measurements
within 15 minutes. All urine samples examined with the GHB
on-site test were also tested using the Viva-E GHB
immunoassay.
Gold Standard
Results of the GHB on-site test and Viva-E GHB
immunoassay were compared with those from the gold
standard method: a validated GC–FID system. A full valida-
tion based on the “Guidelines on Bioanalytical Method Val-
idation” of the European Medicine Agency was successfully
completed before this study.26 The GC–FID system consisted
of an HP 6890 Series G1530A Gas Chromatograph,
a G2613A/G2614A automatic liquid sampler, and a micro-
cell electron capture detector (Agilent Technologies, Am-
stelveen, the Netherlands). The column was a Chrompack,
WCOT-fused silica capillary column (CP-SIL 5 CB, 25 m
· 530 mm, film thickness 500 mm; Agilent Technologies),
at a temperature of 1208C. у-Valerolactone was used as the
internal standard. The method was based on the conversion of
GHB into gamma-butyrolactone in an acid environment.20
GHB Stability in Urine
All measurements were performed within 28 days of
sampling. GHB stability in urine was confirmed in-house
within the 28 days while stored in the refrigerator (2–88C) or
freezer (2208C), for both pooled and synthetic urine at 2
different concentrations (10 and 200 mcg/mL). The recovery
after 28 days was between 95% and 106% in all cases and
was therefore accepted.
Interference of Ethanol
To examine for possible ethanol interference with test
results, ethanol concentrations were measured in urine and
serum samples using the same GC–FID system and column,
at a temperature of 908C. Ethanol concentrations were com-
pared between the true-negative and false-positive groups, to
investigate if ethanol could induce false positives in GHB
negative samples. Serum ethanol concentrations were mea-
sured, given that this specimen is often used for measuring
ethanol concentrations in clinical practice. We also investi-
gated the ethanol concentration in urine because urine ethanol
had the ability to interfere with the tests. Owing to the pos-
sible ethanol interference, the specificity and sensitivity were
equally calculated, excluding samples with a serum ethanol
concentration $2.0 g/L. This cutoff value was used because
these ethanol concentrations are known to increase GHB
levels.25
False-Positive Results
The GHB on-site test’s false positives were subject to
an additional screening in serum to identify possible interfer-
ing substances. The screening method consisted of a multi-
stage mass spectrometer: LC-MSn (LC-MSn AmaZon Speed
ToxTyper; Bruker, Bremen, Germany) system, including an
ultra–high-performance liquid chromatography system
(Dionex ultimate 3000 RS pump, autosampler and column
compartment; Thermo Scientific, Breda, the Netherlands).
The column used was an Acclaim Rapid Separation LC col-
umn (120 C18, 2,1 · 100 mm, film thickness 2.2 mm, 120A;
Thermo Scientific) at a temperature of 408C. Samples were
prepared using a precipitation method with acetonitrile. An
extensive library (Toxtyper 1.1 Library, May 2014) with 900
drugs (including drugs of abuse) and metabolites was used to
identify possible interfering substances.27
Outcomes
The primary outcomes were the specificity and sensi-
tivity of the GHB on-site test and the Viva-E GHB
immunoassay. Specificity and sensitivity were calculated as
follows:
1. Specificity = number of true negatives/(number of true
negatives + number of false-positive samples).
2. Sensitivity = number of true positives/(number of true
positives + number of false-negative samples).
The specificity and sensitivity were calculated for the
regular cutoff value of 10 mcg/mL and a higher value, 50
mcg/mL. According to the OLVG hospital, most patients with
clinically relevant GHB intoxications have .50 mcg/mL
GHB levels. This cutoff has not been described in the existing
literature, but we propose that it can be used to detect clini-
cally relevant GHB intoxications. However, the 50 mcg/mL
cutoff is too high to draw conclusions on patient use of GHB
because urine levels .10 mcg/mL are already associated with
GHB intake.10,20–23
Secondary outcomes included the difference in ethanol
levels between the false-positive and true-negative groups and
possible interfering substances in the false-positive group.
Analyses
The GHB on-site test and the Viva-E GHB immuno-
assay were considered reliable if their specificity and
sensitivity were both .90%. To calculate the sample size,
a 0.95 proportion with a 2-sided confidence interval of 95%
and a total width of 0.10 (0.90–1.00) was used. The Clopper–
Pearson formula was used to calculate the 95% confidence
interval. A sample size of 94 patients with a positive GHB test
and 94 patients with a negative GHB test was required. The
sample size calculation was performed using PASS 14 (NCSS
LLC, Kaysville, UT). IBM SPSS Statistics (version 22; IBM,
Armonk, NY) was used for statistical analyses. Only the
Mann–Whitney U test was used for non-normally distributed
continuous data. P values, 0.05 were considered statistically
significant.
RESULTS
Study Subjects
Of 375 patients included in the study, 103 tested
positive for urine GHB following the gold standard and
a cutoff value of 10 mcg/mL. Patient characteristics are
displayed in Table 1. Most enrolled subjects were men:
81.6% in the GHB-positive and 66.2% in the GHB-negative
group. In the GHB-positive and -negative groups, mainly
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Dutch residents were observed (91% and 71%, respectively).
The GCS score was significantly lower in the GHB-positive
group than in the GHB-negative group (P , 0.001). Serum
samples were obtained from 175 patients.
Specificity and Sensitivity
Based on the results of the GHB on-site test on the 375
obtained urine samples, a total of 121 samples tested positive
and 254 samples negative. Of the GHB-positive patients, 44
were also positive for vitamin C. The GHB on-site test’s
results were therefore unreliable for these patients (following
product information) and, hence, were excluded. Of the 44
excluded patients, 33 tested positive and 11 tested negative
for GHB based on the gold standard method.
The GHB on-site test’s results of the 331 patients left
were used to calculate the specificity and sensitivity for 2
cutoff values, and the results are shown in Tables 2 and 3.
The specificity and sensitivity values for the GHB on-site test
were 90.0% and 72.9%, respectively (cutoff 10 mcg/mL).
More so, the Viva-E GHB immunoassay’s results for all
patients were compared with the gold standard. The specific-
ity and sensitivity values of the Viva-E GHB immunoassay
are shown in Table 3. The specificity and sensitivity values
for the Viva-E GHB immunoassay were 93.6% and 85.0%,
respectively (cutoff, 10 mcg/mL).
Ethanol
Ethanol interference with the GHB on-site test and
Viva-E GHB immunoassay was investigated in all samples.
The urine ethanol concentrations of the true-negative and the
false-positive groups are displayed in Figure 2 (cutoff, 10
mcg/mL). More extensive data on urine and serum ethanol
concentrations are shown in Table 4. Ethanol concentrations
were significantly higher in the false-positive group than the
true-negative group (cutoff, 10 mcg/mL) (P , 0.001). Owing
to the possible interference of ethanol, the specificity and
sensitivity were calculated using a cutoff value of 50 mcg/
mL, excluding samples (41) with a serum ethanol concentra-
tion $2.0 g/L. None of the 41 excluded samples was positive
for GHB (gold standard). For these results, the specificity and
sensitivity of the GHB on-site test were 100% and 72.7%,
respectively, whereas those for the Viva-E GHB immunoas-
say were 99.4% and 93.5%, respectively (Table 3).
Vitamin C
To investigate the actual interference of vitamin C, the
specificity and sensitivity of the GHB on-site test were also
calculated, without excluding vitamin C–positive samples.
Results are shown in Table 3. The specificity decreased from
90.0% to 86.4% when GHB results (cutoff 10 mcg/mL) of
positive vitamin C samples were included in the analyses. The
sensitivity increased from 72.9% to 81.6%.
False Positives
False-positive samples of the GHB on-site test were
qualitatively screened for possible interfering substances in
the serum. Serum samples were available in 15 of the 26
false-positive samples. Detected substances (apart from
ethanol) were highly heterogeneous, containing, for instance,
venlafaxine, baclofen, ethyl glucuronide, midazolam, theo-
bromine, MDMA, MDA, hydrocortisone, cocaine, and ben-
zoylecgonine. No specific substance was identified as
prominent in multiple false-positive samples.
DISCUSSION
To the best of our knowledge, this is the first pro-
spective study regarding tests for urine GHB, which can be
quickly assessed in the hospital. The major findings of this
study were the poor performance of the GHB on-site test and
the possibility of the Viva-E GHB immunoassay being an
acceptable alternative for detecting clinically relevant GHB
intoxications (cutoff, 50 mcg/mL). By contrast, the Viva-E
GHB immunoassay registered poor performance at a cutoff
value of 10 mcg/mL and is therefore unable to detect
exogenous GHB administration in cases of low urinary
concentrations.10,20–23 Compared with the gas chromatogra-
phy method used as the gold standard in this study, the main
advantage of the investigated methods is the ability to obtain
quicker test results. An on-site test for detecting urine GHB
within minutes can be of great diagnostic value in addition to
point-of-care tests for other drugs of abuse.28–35 However, the
goal of achieving a specificity and sensitivity of .90% was
unmet. The GHB on-site test’s specificity was at the border-
line (90.0%), and its sensitivity was unacceptable (72.9%).
Actually, the sensitivity is even worse due to the 33 GHB-
positive patients who were excluded because of a positive
vitamin C test. Moreover, the large number of positive vita-
min C tests (44/121; 36%) makes this test inapplicable for
clinical practice. Vitamin C could have caused a false-positive
result in 11 of the 44 positive vitamin C samples (25%),
which is a substantial percentage. Including the positive vita-
min C samples resulted in increased sensitivity (81.6%) and
TABLE 1. Patient Characteristics
GHB-Positive
(n = 103)
GHB-Negative
(n = 272)
Age, median (IQR, 25–75) 34 (28–39) 34 (23–47)
Male, no. (%) 84 (81.6) 180 (66.2)
Residential country, no. (%)
The Netherlands 94 (91) 194 (71)
Europe (other) 4 (4) 56 (21)
Other/unknown 5 (5) 22 (8)
GCS, median (IQR, 25–75) 3 (3–8) 10 (3–14)
TABLE 2. Correlation Between the GHB On-Site Test and the
Gold Standard GC–FID System
GHB On-Site Test
(Cutoff, 10 mcg/mL)
GC–FID System (Gold Standard)
(Cutoff, 10 mcg/mL)
Positive Negative Total
Positive 51 26 77
Negative 19 235 254
Total 70 261 331
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decreased specificity (,90%). Irrespective of these, the GHB
on-site test is inapplicable for clinical practice.
The Viva-E GHB immunoassay showed better results,
with an acceptable specificity of 93.6%, albeit with an
insufficient sensitivity of 85.0%. This specificity is compara-
ble with the specificity calculated by Hasan et al (98.4%)
using the same assay, but a different cutoff value (15 mcg/
mL). The sensitivity Hasan et al9 found was better: 100%, but
this was based on a small sample size (n = 36) and could
therefore not be fairly compared with our data. The specificity
of both tests was higher when using a higher cutoff value of
50 mcg/mL (GHB on-site test: 96.7% and Viva-E GHB
immunoassay: 99.6%), resulting in less false positives. This
higher cutoff value leads to a higher specificity because inter-
fering agents may have less influence when the test turns
positive at a higher GHB concentration. The sensitivity of
both tests also increased when using the higher cutoff value
of 50 mcg/mL (GHB on-site test: 75.0% and Viva-E GHB
immunoassay: 88.3%). The slight increase in sensitivity was
unexpected but could be explained by the decrease in false-
negative samples at the cutoff of 50 mcg/mL. Specifically, 6
samples had GHB concentrations between 10 and 50 mcg/mL
(gold standard), of which 5 and 4 samples tested negative
(,10 mcg/mL) for the on-site GHB test and the Viva-E
GHB immunoassay, respectively. These false-negative results
were eliminated at the cutoff of 50 mcg/mL. Both tests had
substantial false-negative results (sensitivity ,90%), indicat-
ing that the tests encounter difficulties in detecting GHB.
Nevertheless, the cutoff value of 50 mcg/mL has an
important drawback because it could only indicate clinically
relevant GHB intoxications. A negative result with this cutoff
value could not rule out the fact that the patient suffered from
exogenous GHB administration. The results of the Viva-E
GHB immunoassay should therefore only be used to confirm
a suspicion of GHB intake, and no conclusions should be
drawn upon obtaining negative results. Additional measure-
ments with a chromatographic method are still necessary for
demonstrating exogenous GHB administration.
Given that the number of generated false-negative
results was not acceptable for the GHB on-site test, regardless
of the cutoff value used, the test cannot be safely used to
identify patients who have used GHB. A negative test result
may lead to further diagnostic work-up and adequate patient
diagnosis and treatment. A positive test result may support
physicians in their clinical decision-making and possibly
prevent unnecessary diagnostics. However, false-negative
results may lead to redundant diagnostics and suboptimal
treatment, and even worse, false-positive results may result in
an increased health risk for patients. More specifically, it may
withhold the physician from applying further diagnostic tools,
potentially missing another cause of a decreased GCS score.
Hence, because of the impaired sensitivity of the test, we do
not recommend using the GHB on-site test in clinical
practice.
Our data support the hypothesis that false-positive
results are caused by the concurrent presence of ethanol in
the urine. The specificity of both tests (.90%) was acceptable
and the ethanol influence tolerable. By contrast, the sensitivity
was unexpectedly low, without any concrete explanations.
We postulate that unknown interfering substances present in
the samples probably obstruct or delay enzymatic activity
during the conversion of NAD into NADH+. Conversely,
the specificity and sensitivity of the Viva-E GHB immunoas-
say were good, at a cutoff value of 50 mcg/mL and exclusion
of samples with a serum ethanol concentration $2.0 g/L
(99.4% and 93.5%, respectively). Concomitant use of ethanol
and GHB occurs regularly, especially in drug-facilitated sex-
ual assault where GHB is added to alcoholic beverages.36 In
this population, high ethanol concentrations in combination
with GHB cause toxic effects. Although the specificity of the
test is sufficient (.90%), it is necessary to confirm the
absence or presence of GHB with a validated chromatography
method in case of possible legal matters.
TABLE 3. The Specificity and Sensitivity of the GHB On-Site Test and the Viva-E GHB Immunoassay Calculated With 2 Different
Cutoffs (10 and 50 mcg/mL)
Positive Vitamin C Samples
Included in Analyses
Samples EtOH ‡2.0 g/L
Included in Analyses
Specificity, % Sensitivity, % Specificity, % Sensitivity, %
Cutoff, 10 mcg/mL Cutoff, 50 mcg/mL
GHB on-site test No Yes 90.0 72.9 96.7 75.0
No No 97.5 83.3 100 72.7
Yes Yes 86.4 81.6 96.4 77.1
Viva-E GHB
immunoassay
— Yes 93.6 85.0 99.6 88.3
— No 99.1 74.1 99.4 93.5
EtOH, ethanol.
FIGURE 2. Urine ethanol concentrations for the true-negative
and false-positive groups (cutoff, 10 mcg/mL) of the GHB on-
site test and the Viva-E GHB immunoassay.
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This study covers the analytical validation of the GHB
on-site test and the Viva-E GHB immunoassay. Given that
our expected outcomes were unmet, we conclude that further
improvements of these commercially available on-site tests
are necessary for obtaining a specificity and sensitivity
.90%. This study also emphasizes the importance of validat-
ing all novel on-site and laboratory tests before implementa-
tion in clinical practice. More so, before implementing a test
in clinical practice at the ED, the clinical relevance should be
studied by investigating whether a quickly available GHB
level contributes to patient outcome.
A limitation of this study is that the GHB on-site test
was performed by laboratory workers of the pharmaceutical
laboratory in the hospital pharmacy. Ideally, after imple-
mentation in clinical practice, the GHB on-site test is used
by ED nurses or physicians for fast results at the point-of-
care, although laboratory workers are specifically trained to
perform different types of analyses and to follow standard
operating procedures. The sometimes-hectic ED is a sub-
optimal place to perform an analytical test. Critical steps in
the analytical procedure of the GHB on-site test are reading
the results after a given time, performing an additional test
for vitamin C, and comparing the color of the dipstick with
reference colors. The specificity and sensitivity of the test
may, therefore, be different in a real-life setting, where the
test is operated by nurses or physicians at the point-of-care.
However, the analytical validation is preferably performed
by laboratory workers to assess the performance of the test
itself, without external interfering factors. Hence, this study
was suitable to study the performance of the GHB on-site
test.
Second, the required sample size of 94 positive patients
was not achieved for the GHB on-site test because of sample
exclusion (vitamin C–positive samples).19 This has im-
plications for the reliability of the calculated specificity and
sensitivity of the GHB on-site test. However, the large
number of positive vitamin C results in this study population
makes this test unusable in clinical practice. Moreover, the
sample size was sufficient to determine the specificity and
sensitivity for the Viva-E GHB immunoassay, where vitamin
C measurements and eventual exclusions were not required.
Finally, our sample GHB concentrations were not
considered very challenging for the test. Only 13 of the 375
tested samples had a GHB concentration between 5 and 100
mcg/mL (gold standard), within the range of the cutoff values.
The other samples were either negative or clearly positive
(.100 mcg/mL). To challenge these tests, it would have been
better to have more samples around the cutoff values of 10
and 50 mcg/mL. On the other hand, real patient samples were
used in this study, reflecting GHB levels seen in clinical
practice.
CONCLUSIONS
In summary, the DrugCheck GHB on-site test showed
a specificity and sensitivity of 90.0% and 72.9%, respectively.
Therefore, we do not recommend this GHB on-site test be
implemented at the ED. The Viva-E GHB immunoassay
would be an acceptable alternative to detect clinically relevant
GHB intoxications using a cutoff of 50 mcg/mL, provided
patients with a serum ethanol concentration $2.0 g/L are
excluded. Under these conditions, the specificity and sensi-
tivity of the Viva-E GHB immunoassay were 99.4% and
93.5%, respectively.
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